SEATTLE, WA (July 20, 2015): Quorum Review IRB, the premier central IRB, is introducing a comprehensive program that supports the unique needs of Phase I Healthy clinical trials. Quorum knows that Phase I units require immediate service and quick turnaround times. Quorum’s new program delivers.
With Quorum Review’s new Phase 1 Healthy Program, a study can be ready to enroll participants within a few days of submitting their materials. For changes mid-study, review and delivery of approval documents is even faster. Quorum’s new program also provides unprecedented alternatives in the review of recruitment materials. Quorum can conditionally approve recruitment materials before the protocol review is finalized, so you can more proactively plan for their deployment. If your group leverages generic recruitment templates and generic screening consent forms, Quorum’s new program makes using those materials easier than ever.
Quorum’s customers that have had the opportunity to preview the new Phase 1 Healthy Program proclaim it to be the “most intuitive service offering that exists for Phase 1 Healthy research.” “We know Phase I,” says Quorum’s CEO, Cami Gearhart. “We have Phase I researchers on our IRB panels and staff dedicated to supporting Phase I services. We are proud to offer our clients nimble turnaround times as well as the reliability of a large, accredited IRB.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.